Zydus Lifesciences Announces Board Meeting to Discuss Potential Share Repurchase.

Zydus Lifesciences to Consider Share Buyback Proposal at Upcoming Board Meeting

Pharmaceutical major Zydus Lifesciences will be in focus today after informing exchanges that its Board of Directors will consider a proposal for the buyback of fully paid-up equity shares at its upcoming meeting scheduled for May 19, 2026, along with the company's financial results.

According to a regulatory filing issued on May 13, the pharmaceutical major stated that the board would evaluate the buyback proposal in accordance with applicable provisions under the Companies Act, SEBI Buy-back Regulations and other relevant laws. The company clarified that the proposal would be discussed at the same board meeting that was earlier scheduled to consider the company's quarterly and annual financial results.

The company had previously informed exchanges on May 8 regarding the board meeting. Zydus also stated that the trading window for directors and designated persons under SEBI's insider trading regulations will remain closed until May 21, 2026, and will reopen for trading from May 22, 2026. The restriction will also apply in relation to the proposed buyback process.

Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data

Share buybacks are often used by companies to return surplus cash to shareholders and optimize capital allocation. They can also reduce the number of outstanding shares in the market, which may support shareholder returns over the longer term.

Zydus Lifesciences Q3 Results Comparison

Zydus Lifesciences posted a 30% year-on-year increase in revenue from operations to ₹6,864.50 crore for the quarter ended December, supported by strong performance across its major business segments, including consumer wellness, North America formulations and international markets. The Ahmedabad-based drug maker reported a marginal 2% rise in net profit to ₹1,042 crore during the quarter. Profit growth was affected by a one-time adjustment related to gratuity and leave encashment liabilities following the implementation of the government's new labour code.

Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline

Excluding the impact of the one-time adjustment, the company's net profit increased 9% year-on-year to ₹1,110 crore. The results for the quarter ended March 2026 (Q4FY26) will also be declared on May 19.

Zydus Lifesciences Stock Performance

The pharma stock hit its 52-week high of ₹1,059 per share in September 2025 and its 52-week low of ₹835.85 in March 2026. It has been flat but in the red, down 0.5% in the last 1 month; however, it added 26% in the last 3 months. In 1 year, the pharma stock has gained 43%.